

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot #	Exp Date	NDC	UPC
PAPAV HCL INJ 30MG/ML ORY 10@	21VPHI023	06/30/2023	72516002410	37251602410
PAPAVERINE HCL 60MG/2ML ORY25@	21VPHI022	06/30/2023	72516002425	37251602425
	21VPHI021	06/30/2023		
	20VPHI039	12/31/2022		
	20VPHI038	12/31/2022		
	20VPHI037	12/31/2022		

Vitae Enem Vitae (VeV), contract manufacturer for the Oryza Pharmaceuticals products above, is recalling the above item(s)/lot(s) due to potential deviations from GMP practices. This recall is to the retail level. Affected product started shipping May 2021.